Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LSM3 homolog, U6 small nuclear RNA and mRNA degradation associated pseudogene 2 (LSM3P2)
- Target
- LSM3P2
- Molecular classification
- Other (processed pseudogene, retrocopy), Not a member of canonical protein families (such as GPCR, ion channel, enzyme, receptor, etc.)
01
Overview
LSM3P2 is a **processed pseudogene**, specifically a retrocopy of the parental protein-coding gene LSM3[4]. LSM3 itself encodes a Sm-like protein involved in U6 small nuclear RNA stability and pre-mRNA splicing, as well as mRNA degradation pathways, but LSM3P2 does not produce a functional protein[1][2][10]. While some pseudogenes may acquire regulatory functions or impact gene expression through non-coding RNA mechanisms, there is currently no evidence that LSM3P2 plays a significant regulatory or disease-related role. It is not conserved across major species and is not characterized as a protein-coding, druggable, or canonical molecular target[4][5][7][8].
- Other names
- LSM3P2 (most commonly used abbreviation)LSM3 pseudogene 2LSM3 homolog, U6 small nuclear RNA and mRNA degradation associated pseudogene 2
02
Mechanism of action
None (not a drug target, no mechanisms of action described)
03
Biological functions
Other (non-coding RNA, uncharacterized regulatory roles possible; pseudogene transcripts can sometimes regulate other genes via RNA interference)No direct biological function as a protein
04
Disease associations
Other (processed pseudogenes may have regulatory effects or be involved in genome evolution and diseases, but there is no direct evidence linking LSM3P2 specifically to a disease)No established role in cancer, inflammation, neurodegeneration, etc.
Beyond the preview
Go deeper on LSM3 homolog, U6 small nuclear RNA and mRNA degradation associated pseudogene 2 (LSM3P2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LSM3 homolog, U6 small nuclear RNA and mRNA degradation associated pseudogene 2 (LSM3P2).